NFDI4DS | UHH-SEMS - Publication Details

Amir Alpert

ORCID: 0000-0002-1274-1813

Publications

Citations

Views

---

Saved

---

About

Contact & Profiles

A5052267290

Research Areas

CAR-T cell therapy research
Cancer Research and Treatments
Biomedical Ethics and Regulation
Virus-based gene therapy research
Immunotherapy and Immune Responses
Immune Cell Function and Interaction
T-cell and B-cell Immunology
Biochemical and Molecular Research
Monoclonal and Polyclonal Antibodies Research
CRISPR and Genetic Engineering
Acute Lymphoblastic Leukemia research
Genomics and Chromatin Dynamics
DNA Repair Mechanisms

The University of Texas MD Anderson Cancer Center
2020

University of Houston
2015

The University of Texas at Austin
2012-2015

Quantitative immunopeptidomics reveals a tumor stroma–specific target for T cell therapy

OPENALEX - Publications

Gloria B. Kim Jens Fritsche Sebastian Bunk Andrea Mahr Felix Unverdorben and 37 more

T cell receptor (TCR)-based immunotherapy has emerged as a promising therapeutic approach for the treatment of patients with solid cancers. Identifying peptide-human leukocyte antigen (pHLA) complexes highly presented on tumors and rarely expressed healthy tissue in combination high-affinity TCRs that when introduced into cells can redirect to eliminate tumor but not is key requirement safe efficacious TCR-based therapies. To discover shared antigens could be targeted via adoptive therapy,...

10.1126/scitranslmed.abo6135 article EN Science Translational Medicine 2022-08-31

Systematic Identification of Functional Residues in Mammalian Histone H2AX

OPENALEX - Publications

Wei‐Ta Chen Amir Alpert Courtney Leiter Fade Gong Stephen P. Jackson and 1 more

The histone variant H2AX is a principal component of chromatin involved in the detection, signaling, and repair DNA double-strand breaks (DSBs). thought to operate primarily through its C-terminal S139 phosphorylation, which mediates recruitment damage response (DDR) factors at DSB sites. Here, we describe comprehensive screen 67 residues determine their contributions functions. Our analysis revealed that both sumoylated ubiquitylated. Individual defective for sumoylation, ubiquitylation,...

10.1128/mcb.01024-12 article EN Molecular and Cellular Biology 2012-10-30

Dihydrofolate Reductase and Thymidylate Synthase Transgenes Resistant to Methotrexate Interact to Permit Novel Transgene Regulation

OPENALEX - Publications

David Rushworth Amber Mathews Amir Alpert Laurence J.N. Cooper

10.1074/jbc.c115.671123 article EN cc-by Journal of Biological Chemistry 2015-08-05

Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer

OPENALEX - Publications

Apostolia M. Tsimberidou Kerstin Guenther Börje S. Andersson Regina Mendrzyk Amir Alpert and 36 more

Abstract IMA101 is an actively personalized, multi-targeted adoptive cell therapy (ACT), whereby autologous T cells are directed against multiple novel defined peptide-HLA (pHLA) cancer targets. HLA-A*02:01-positive patients with relapsed/refractory solid tumors expressing ≥1 of 8 predefined targets underwent leukapheresis. Endogenous specific for up to 4 were primed and expanded in vitro. Patients received lymphodepletion (fludarabine, cyclophosphamide), followed by T-cell infusion low-dose...

10.1158/2326-6066.cir-22-0444 article EN Cancer Immunology Research 2023-05-12

Very rapid cloning, expression and identifying specificity of T-cell receptors for T-cell engineering

OPENALEX - Publications

Shan Zong Tiejuan Mi Leo G. Flores Amir Alpert Simon Olivares and 5 more

Neoantigens can be predicted and in some cases identified using the data obtained from whole exome sequencing transcriptome of tumor cells. These coupled with single-cell RNA for direct interrogation transcriptome, surfaceome, pairing αβ T-cell receptors (TCRαβ) hundreds single T Using these 2 large datasets, we established a platform identifying antigens recognized by TCRαβs Our approach is based on rapid expression cloned TCRαβ genes as Sleeping Beauty transposons determination introduced...

10.1371/journal.pone.0228112 article EN cc-by PLoS ONE 2020-02-10

Supplemental Figure 10 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer

OPENALEX - Publications

Apostolia M. Tsimberidou Kerstin Guenther Börje S. Andersson Regina Mendrzyk Amir Alpert and 36 more

Supplemental Figure 10

10.1158/2326-6066.27026579.v1 preprint NL 2024-09-16

Supplemental Figure 3 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer

OPENALEX - Publications

Apostolia M. Tsimberidou Kerstin Guenther Börje S. Andersson Regina Mendrzyk Amir Alpert and 36 more

Supplemental Figure 3

10.1158/2326-6066.27026573 preprint NL 2024-09-16

Supplemental Figure 2 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer

OPENALEX - Publications

Apostolia M. Tsimberidou Kerstin Guenther Börje S. Andersson Regina Mendrzyk Amir Alpert and 36 more

Supplemental Figure 2

10.1158/2326-6066.27026576 preprint NL 2024-09-16

Supplemental Figure 4 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer

OPENALEX - Publications

Apostolia M. Tsimberidou Kerstin Guenther Börje S. Andersson Regina Mendrzyk Amir Alpert and 36 more

Supplemental Figure 4

10.1158/2326-6066.27026570.v1 preprint NL 2024-09-16

Supplemental Figure 4 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer

OPENALEX - Publications

Apostolia M. Tsimberidou Kerstin Guenther Börje S. Andersson Regina Mendrzyk Amir Alpert and 36 more

Supplemental Figure 4

10.1158/2326-6066.27026570 preprint NL 2024-09-16

Supplemental Figure 5 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer

OPENALEX - Publications

Apostolia M. Tsimberidou Kerstin Guenther Börje S. Andersson Regina Mendrzyk Amir Alpert and 36 more

Supplemental Figure 5

10.1158/2326-6066.27026567.v1 preprint NL 2024-09-16

Supplemental Figure 3 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer

OPENALEX - Publications

Apostolia M. Tsimberidou Kerstin Guenther Börje S. Andersson Regina Mendrzyk Amir Alpert and 36 more

Supplemental Figure 3

10.1158/2326-6066.27026573.v1 preprint NL 2024-09-16

Supplemental Figure 2 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer

OPENALEX - Publications

Apostolia M. Tsimberidou Kerstin Guenther Börje S. Andersson Regina Mendrzyk Amir Alpert and 36 more

Supplemental Figure 2

10.1158/2326-6066.27026576.v1 preprint NL 2024-09-16

Supplemental Figure 8 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer

OPENALEX - Publications

Apostolia M. Tsimberidou Kerstin Guenther Börje S. Andersson Regina Mendrzyk Amir Alpert and 36 more

Supplemental Figure 8

10.1158/2326-6066.27026558 preprint NL 2024-09-16

Supplemental Figure 1 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer

OPENALEX - Publications

Apostolia M. Tsimberidou Kerstin Guenther Börje S. Andersson Regina Mendrzyk Amir Alpert and 36 more

Supplemental Figure 1

10.1158/2326-6066.27026582 preprint NL 2024-09-16

Supplemental Figure 10 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer

OPENALEX - Publications

Apostolia M. Tsimberidou Kerstin Guenther Börje S. Andersson Regina Mendrzyk Amir Alpert and 36 more

Supplemental Figure 10

10.1158/2326-6066.27026579 preprint NL 2024-09-16

Supplemental Figure 9 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer

OPENALEX - Publications

Apostolia M. Tsimberidou Kerstin Guenther Börje S. Andersson Regina Mendrzyk Amir Alpert and 36 more

Supplemental Figure 9

10.1158/2326-6066.27026555 preprint NL 2024-09-16

Supplemental Figure 5 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer

OPENALEX - Publications

Apostolia M. Tsimberidou Kerstin Guenther Börje S. Andersson Regina Mendrzyk Amir Alpert and 36 more

Supplemental Figure 5

10.1158/2326-6066.27026567 preprint NL 2024-09-16

Supplemental Figure 6 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer

OPENALEX - Publications

Apostolia M. Tsimberidou Kerstin Guenther Börje S. Andersson Regina Mendrzyk Amir Alpert and 36 more

Supplemental Figure 6

10.1158/2326-6066.27026564 preprint NL 2024-09-16

Supplemental Figure 1 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer

OPENALEX - Publications

Apostolia M. Tsimberidou Kerstin Guenther Börje S. Andersson Regina Mendrzyk Amir Alpert and 36 more

Supplemental Figure 1

10.1158/2326-6066.27026582.v1 preprint NL 2024-09-16

Supplemental Figure 8 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer

OPENALEX - Publications

Apostolia M. Tsimberidou Kerstin Guenther Börje S. Andersson Regina Mendrzyk Amir Alpert and 36 more

Supplemental Figure 8

10.1158/2326-6066.27026558.v1 preprint NL 2024-09-16

Supplemental Figure 7 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer

OPENALEX - Publications

Apostolia M. Tsimberidou Kerstin Guenther Börje S. Andersson Regina Mendrzyk Amir Alpert and 36 more

Supplemental Figure 7

10.1158/2326-6066.27026561 preprint NL 2024-09-16

Supplemental Figure 6 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer

OPENALEX - Publications

Apostolia M. Tsimberidou Kerstin Guenther Börje S. Andersson Regina Mendrzyk Amir Alpert and 36 more

Supplemental Figure 6

10.1158/2326-6066.27026564.v1 preprint NL 2024-09-16

Supplemental Figure 9 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer

OPENALEX - Publications

Apostolia M. Tsimberidou Kerstin Guenther Börje S. Andersson Regina Mendrzyk Amir Alpert and 36 more

Supplemental Figure 9

10.1158/2326-6066.27026555.v1 preprint NL 2024-09-16

Supplemental Figure 7 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer

OPENALEX - Publications

Apostolia M. Tsimberidou Kerstin Guenther Börje S. Andersson Regina Mendrzyk Amir Alpert and 36 more

Supplemental Figure 7

10.1158/2326-6066.27026561.v1 preprint NL 2024-09-16

Coming Soon ...